IMPROVE bleeding risk score: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
# | __NOTOC__ | ||
{{CMG}}; {{AE}} {{Rim}} | |||
==Overview== | |||
===IMPROVE Bleeding Risk Score=== | |||
===Calculation of the IMPROVE Bleeding Risk Score=== | |||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Variable'''||style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Score'''<ref name="pmid20453069">{{cite journal| author=Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK et al.| title=Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. | journal=Chest | year= 2011 | volume= 139 | issue= 1 | pages= 69-79 | pmid=20453069 | doi=10.1378/chest.09-3081 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20453069 }} </ref> | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Active [[gastric ulcer|gastric]] or [[duodenal ulcer]] || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |4.5 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Prior [[bleeding]] within the last 3 months|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |4 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |[[Thrombocytopenia]] (<50x10<sup>9</sup>/L)||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |4 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Age ≥ 85 years||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |3.5 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |[[Liver failure]] ([[INR]]>1.5)||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2.5 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |[[Kidney failure|Severe kidney failure]] ([[GFR]]< 30 mL/min/m<sup>2</sup>)||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2.5 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Admission to [[ICU]] or [[CCU]]||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2.5 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |[[Central venous catheter]]||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Rheumatic disease||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Active [[malignancy]]||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Age: 40-84 years|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1.5 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Male||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1 | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |[[Kidney failure|Moderate kidney failure]] ([[GFR]]: 30-59 mL/min/m<sup>2</sup>)||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1 | |||
|} | |||
===Interpretation of the IMPROVE Bleeding Risk Score=== | |||
The IMPROVE risk score for bleeding can be interpreted as such:<ref name="pmid20453069">{{cite journal| author=Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK et al.| title=Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. | journal=Chest | year= 2011 | volume= 139 | issue= 1 | pages= 69-79 | pmid=20453069 | doi=10.1378/chest.09-3081 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20453069 }} </ref> | |||
* '''Score ≥7: Elevated risk of bleeding''' | |||
* '''Score <7: Not elevated risk of bleeding''' | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Cardiology]] | |||
[[Category:Up-To-Date]] |
Revision as of 00:22, 27 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
IMPROVE Bleeding Risk Score
Calculation of the IMPROVE Bleeding Risk Score
Variable | Score[1] |
Active gastric or duodenal ulcer | 4.5 |
Prior bleeding within the last 3 months | 4 |
Thrombocytopenia (<50x109/L) | 4 |
Age ≥ 85 years | 3.5 |
Liver failure (INR>1.5) | 2.5 |
Severe kidney failure (GFR< 30 mL/min/m2) | 2.5 |
Admission to ICU or CCU | 2.5 |
Central venous catheter | 2 |
Rheumatic disease | 2 |
Active malignancy | 2 |
Age: 40-84 years | 1.5 |
Male | 1 |
Moderate kidney failure (GFR: 30-59 mL/min/m2) | 1 |
Interpretation of the IMPROVE Bleeding Risk Score
The IMPROVE risk score for bleeding can be interpreted as such:[1]
- Score ≥7: Elevated risk of bleeding
- Score <7: Not elevated risk of bleeding
References
- ↑ 1.0 1.1 Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK; et al. (2011). "Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators". Chest. 139 (1): 69–79. doi:10.1378/chest.09-3081. PMID 20453069.